FDA to review udenafil for use in single ventricle disease

Udenafil, a novel phosphodiesterase-5 inhibitor, is currently under investigation for use to improve symptoms in patients after a palliative Fontan procedure. The FDA granted orphan designation for this treatment previously.

Source:

Biospace Inc.